\$162

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

DATE: _

BOX PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

: Group Art Unit: 1652

Emil C. Gotschlich

Appln. No.:

10/007,267

: Examiner: To Be Assigned

Filed:

December 3, 2001

Attorney Docket

For:

GLYCOSYLTRANSFERASES FOR

: No. 040853-01-5029-02

BIOSYNTHESIS OF OLIGOSACCHARIDES AND GENES RECEIVED

COPY OF PAPERS ORIGINALLY FILED

ENCODING THEM

APR 2 6 2002

AMENDMENT TRANSMITTAL LETTER

TECH CENTER 1600/2900

Transmitted herewith is an Amendment in the above-identified application.

Substitute Specification.

Small Entity status: [X]

> [X] has previously been claimed/established.

is hereby claimed under 37 C.F.R. §1.27, as [] an Independent Inventor, or [] a Small Business Concern, or [] a Non-Profit Organization.

The additional claim fees have been calculated as follows:

				SMALL ENTITY		LARGE ENTITY		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	16	(-)	20		x\$9		x\$18	
INDEP.	6	(-)	3	3	x\$42	126.00	x\$84	
1 1 Ist PRESENTATION OF MULTIPLE DEPENDENT CLAIMS					x\$140		+\$280	
					TOTAL	\$126.00	TOTAL	

The additional claim fees are being paid by:

A check in the amount of \$_____.

- [X] Authorization to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 040853-01-5029-02)** as noted below. A duplicate copy of this sheet is enclosed.
 - [X] Any overpayments or deficiencies in the above-calculated fee.
 - [X] Additional claim fee in the amount of \$126.00 as calculated above.
 - [X] Any additional fees required under 37 C.F.R. § 1.16 and/or § 1.17.
 - [] In the event that a Petition for Extension of Time is required, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account.

CORRESPONDENCE ADDRESS

April 12, 2007 (Date)

By:

KATHRYN DOYLE, Ph.D, J.D.

Registration No. 36,317

MORGAN, LEWIS & BOCKIUS, LLP

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: (215) 963-5000 Direct Dial: (215) 963-4723

Facsimile: (215) 963-5299

E-Mail: kdoyle@morganlewis.com

Attorney for Applicants

KD/kck Enclosures

der

BOX PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

Emil C. Gotschlich

: Group Art Unit: 1652

APR 2 6 2002

Appln. No.:

10/007,267

: Examiner: To Be Assigned ECH CENTER 1600/29

Filed:

December 3, 2001

Attorney Docket

For:

GLYCOSYLTRANSFERASES FOR

No. 040853-01-5029-02

BIOSYNTHESIS OF

OLIGOSACCHARIDES AND GENES

ENCODING THEM

COPY OF PAPERS ORIGINALLY FILES

SECOND PRELIMINARY AMENDMENT

Preliminary to the examination of the above-identified application, please amend the application as follows:

In the claims:

Please cancel claims 27, 32, and 33, without prejudice. Please add new claims 34-49, as follows:

- 34. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:2, or a functionally active fragment thereof.
- 35. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:3, or a functionally active fragment thereof.
- 36. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:4, or a functionally active fragment thereof.
- 37. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:5, or a functionally active fragment thereof.
- 38. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID ctionally active fragment thereof.

 39. (New) A composition comprising a glycosyltransferase conjugated to a solid NO:6, or a functionally active fragment thereof.
- phase support, wherein the glycosyltransferase is selected from the group consisting of:
- wherein the glycosyltransferase is selected from the group consisting of:

 a) a glycosyltransferase comprising the amino acid sequence SEQ ID NO:2, or a ctive fragment thereof; functionally active fragment thereof;

126.00 CH

1-PH/1559853.1